Here, by conducting FoxP1 gain- and loss-of-function studies, we identify skeletal-muscle FoxP1 as a negative regulator of the skeletal-muscle clock that plays a key role in disrupting circadian patterns of gene expression in response to cancer. The gene discussed is FOXP1; the disease is cancer.